头颈部肉瘤的诊断与治疗现状

doi:10.19438/j.cjoms.2024.04.015

中国口腔颌面外科杂志 ›› 2024, Vol. 22 ›› Issue (4): 404-408.doi: 10.19438/j.cjoms.2024.04.015

头颈部肉瘤的诊断与治疗现状

郭逸飞¹, 张永红¹, 任振虎²

1.河南大学淮河医院口腔科,河南开封 475000;
2.上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,上海交通大学口腔医学院, 国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海市口腔医学研究所,上海 200011

收稿日期:2023-11-02 修回日期:2024-01-06 出版日期:2024-07-20 发布日期:2024-08-07
通讯作者: 任振虎,E-mail:zhenhuren@126.com
作者简介:郭逸飞（1998-）,男,硕士,E-mail:1158991434@qq.com

Diagnosis and treatment of head and neck sarcoma

GUO Yi-fei¹, ZHANG Yong-hong¹, REN Zhen-hu²

1. Department of Stomatology, Huaihe Hospital of Henan University. Kaifeng 475000, Henan Province;
2. Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center of Oral Disease; Shanghai Key laboratory of Stomatology; Shanghai Research Institute of Stomatology. Shanghai 200011, China

Received:2023-11-02 Revised:2024-01-06 Online:2024-07-20 Published:2024-08-07

摘要/Abstract

摘要： 肉瘤是一种低发型恶性肿瘤,头颈部肉瘤的发病率更低。由于肉瘤发生的概率较低且早期临床症状不明显,其诊断比较困难,需要综合临床症状及影像学、病理学、肿瘤标志物等进行诊断。当前肉瘤治疗的关键方法仍然是扩大切除。化疗、放疗、靶向及免疫治疗等可增强治疗效果或改善预后,新型生物标志物及光动力疗法等研究的进展能够对未来肉瘤的诊治提供更多手段。本文对目前头颈部肉瘤主流的诊治方法进行综述,并对未来诊治进行展望。

关键词: 头颈部肉瘤, 诊断, 生物标志物, 手术治疗, 辅助放化疗

Abstract: Sarcoma is a low-occurrence malignant tumor,head and neck sarcoma has a lower incidence rate. Due to the low probability of sarcoma and the lack of obvious early clinical symptoms, it is difficult to diagnose before treatment. Diagnosis needs to integrate clinical symptoms and imaging, pathological findings, and tumor markers, etc. At present, the key technical point for treatment of sarcoma is still wide margin surgery. Chemotherapy, radiotherapy, targeted and immunotherapy can enhance the treatment effect or improve the prognosis. Advances in research on new biomarkers and photodynamic therapy can provide more ways for the diagnosis and treatment of sarcomas in the future. The purpose of this article is to briefly describe the current mainstream diagnosis and treatment methods for head and neck sarcomas and prospects for future diagnosis and treatment.

Key words: Head and neck sarcoma, Diagnosis, Biomarkers, Surgical treatment, Adjuvant radiotherapy and chemotherapy

中图分类号:

R739.8

郭逸飞, 张永红, 任振虎. 头颈部肉瘤的诊断与治疗现状[J]. 中国口腔颌面外科杂志, 2024, 22(4): 404-408.

GUO Yi-fei, ZHANG Yong-hong, REN Zhen-hu. Diagnosis and treatment of head and neck sarcoma[J]. China J Oral Maxillofac Surg, 2024, 22(4): 404-408.

参考文献

[1] Kobayashi K, Hanai N, Yoshimoto S, et al.Current topics and management of head and neck sarcomas[J]. Jpn J Clin Oncol, 2023, 53(9):743-756.
[2] Grünewald TG, Alonso M, Avnet S, et al.Sarcoma treatment in the era of molecular medicine[J]. EMBO Mol Med, 2020, 12(11): e11131.
[3] Peng KA, Grogan T, Wang MB.Head and neck sarcomas: analysis of the SEER Database[J]. Otolaryngol Head Neck Surg, 2014, 151(4): 627-633.
[4] Mirabello L, Troisi RJ, Savage SA.Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program[J]. Cancer, 2009, 115(7): 1531-1543.
[5] Chen YM, Gokavarapu S, Shen QC, et al.Chemotherapy in head and neck osteosarcoma: adjuvant chemotherapy improves overall survival[J]. Oral Oncol, 2017, 73(1): 124-131.
[6] Atarbashi-Moghadam S, Emami Razavi AN, Salehi Zalani S.Prevalence of head and neck sarcoma in a major cancer center in Iran-a 10-year study[J]. Iran J Otorhinolaryngol, 2019, 31(103): 97-102.
[7] Subhawong TK, Wilky BA.Value added: functional MR imaging in management of bone and soft tissue sarcomas[J]. Curr Opin Oncol, 2015, 27(4): 323-231.
[8] Crozat A, Aman P, Mandahl N, et al.Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma[J]. Nature, 1993, 363(6430): 640-644.
[9] Hahm KB, Cho K, Lee C, et al.Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein[J].Nat Genet, 1999, 23(2): 222-227.
[10] Roeb W, Boyer A, Cavenee WK, et al.PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation ofEGR1[J]. Proc Natl Acad Sci USA, 2007, 104(46): 18085-18090.
[11] Wunder JS, Eppert K, Burrow SR, et al.Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas[J]. Oncogene, 1999,18(3): 783-788.
[12] Martin S, Clark SE, Gerrand C, et al.Patients' experiences of a sarcoma diagnosis: a process mapping exercise of diagnostic pathways[J].Cancers (Basel), 2023, 15(15): 3946.
[13] Sarcoma UK. Impact of sarcoma: national sarcoma survey2020[R/OL]. https://sarcoma.org.uk/wp-content/uploads/2022/05/impact_of_sarcoma_2020_national_sarcoma_survey_-_technical_report_-_accessible.pdf.
[14] 戴振霖, 艾哈迈德·阿德热罕穆, 陈一铭, 等. 新辅助化疗治疗头颈部骨肉瘤单中心临床效果回顾[J]. 中国口腔颌面外科杂志, 2021, 19(2): 132-137.
Dai ZL, Aihamaide A, Chen YM, et al.Clinical efficacy of neoadjuvant chemotherapy in the treatment of head and neck osteosarcoma[J]. China Journal of Oral and Maxillofacial Surgery, 2019, 19(2): 132-137.
[15] Patrikidou A, Domont J, Cioffi A, et al.Treating soft tissue sarcomas with adjuvant chemotherapy[J]. Curr Treat Options Oncol, 2011, 12(1): 21-31.
[16] National Comprehensive Cancer Network. NCCN guideline for bone cancer.Version 1[Z/OL]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418.
[17] 张陈平. 口腔癌的间室外科[C]//2011国际暨全国第十一届头颈肿瘤学术大会会议论文集. 杭州: 中国抗癌协会, 2011.
Zhang CP.The interfacial department of oral cancer[C]//Proceedings of the 11th International and National Academic Congress on Head and Neck Oncology in 2011. Hangzhou: Chinese Anti-Cancer Association, 2011.
[18] 贾东东, 夏李明, 金谷, 等. 软组织肉瘤外科治疗进展[J].肿瘤学杂志, 2018, 24(8): 823-827.
Jia DD, Xia LM, Jin G, et al.Surgical treatment of soft tissue sarcoma[J]. Journal of Oncology, 2018, 24(8): 823-827.
[19] Sakamoto A, Iwamoto Y.Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy[J]. Rev Recent Clin Trials, 2008,3(3): 228-231.
[20] Judson I, Verweij J, Gelderblom H, et al.Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlledphase 3 trial[J]. Lancet Oncol,2014, 15(4): 415-423.
[21] 邱蔚六, 郑家伟. 应重视口腔颌面部恶性肿瘤的综合序列治疗[J]. 中国口腔颌面外科杂志, 2005, 3(3):179-182.
Qiu WL, Zheng JW.Comprehensive sequential therapy for oral and maxillofacial malignancy[J]. China Journal of Oral and Maxillofacial Surgery, 2005, 3(3): 179-182.
[22] Thariat J, Schouman T, Brouchet A, et al.Osteosarcomas of the mandible: multidisciplinary manage-ment of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE[J]. Ann Oncol, 2013, 24(3):824-831.
[23] 李晓, 季彤. 颌面头颈部骨肉瘤化学治疗的研究进展[J].国际口腔医学杂志, 2017, 44(1): 83-86.
Li X, Ji T.Research progress of chemotherapy for maxillofacial head and neck osteosarcoma[J]. International Journal of Stomatology, 2017, 44(1): 83-86.
[24] Yoon SS, Chen YL, Kirsch DC, et al.Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas[J]. Ann Surg Oncol, 2010, 17(6): 1515-1529.
[25] Dangoor A, Seddon B, Gerrand C, et al.UK guidelines for the management of soft tissue sarcomas[J]. Clin Sarcoma Res, 2016, 6(1):20-46.
[26] Smithey BE, Pappo AS, Hill DA.C-kit expression in pediatric solid tumors: a comparative immunohistochemical study[J]. Am J Surg Pathol, 2002, 26(4): 486-492.
[27] Wilhelm SM, Carter C, Tang L, et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res, 2004, 64(19): 7099-7109.
[28] 崔抗, 赵瑞华, 冯涵. 软组织肉瘤靶向治疗药物的研究进展[J].中国临床新医学, 2019, 12(4): 366-371.
Cui K, Zhao RH, Feng H.Research progress of targeted therapeutic drugs for soft tissue sarcoma[J]. Chinese Journal of Clinical Oncology, 2019, 12(4): 366-371.
[29] 季彤. 头颈部骨肉瘤规范化诊断与治疗[C]//2019第一届全国口腔颌面-头颈肿瘤学术大会—聚合引领、协同发展论文汇编.上海: 中华口腔医学会, 2019.
Ji T.Standardized diagnosis and treatment of head and neck osteosarcoma[C]//2019 the first national oral and maxillofacial-head and neck tumor academic conference--aggregation leading and collaborative development. Shanghai: Chinese Stomatological Association, 2019.
[30] Matsubara T, Kusuzaki K, Matsumine A, et al.Acridine orange used for photodynamic therapy accumulates in malignant musculoskeletal tumors depending on pH gradient[J]. Anticancer Res, 2006, 26(1A): 187-193.
[31] Matsubara T, Kusuzaki K, Matsumine A, et al.Can a less radical surgery using photodynamic therapy with acridine orange be equal to a wide-margin resection?[J]. Clin Orthop Relat Res, 2013, 471(3): 792-802.
[32] Kusuzaki K, Takai T, Yoshimura H, et al.Clinical trial of radiotherapy after intravenous injection of acridine orange for patients with cancer[J].Anticancer Res, 2018, 38(1): 481-489.
[33] Martano M, Morello E, Avnet S, et al.Photodynamic surgery for feline injection-site sarcoma[J].BioMed Res Int, 2019: 8275935.
[34] 陈一铭, Ahmed, 季彤, 等. 101例头颈部横纹肌肉瘤临床、病理及预后分析[J].中国口腔颌面外科杂志, 2022, 20(2): 146-150.
Chen YM, Ahmed, Ji T, et al.Clinical, pathological and prognostic analysis of 101 cases of rhabdomyosarcoma of head and neck[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(2): 146-150.

头颈部肉瘤的诊断与治疗现状

Diagnosis and treatment of head and neck sarcoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王菡韶, 魏文斌, 赵洪波, 张亚莹, 朱凌, 陈敏洁. 能谱CT单能量成像在颌骨骨髓炎病灶显示中的应用价值评价[J]. 中国口腔颌面外科杂志, 2024, 22(5): 435-439.
[2]	王雪, 张宁. 810 nm波长半导体激光治疗口腔黏液腺囊肿的临床疗效观察[J]. 中国口腔颌面外科杂志, 2024, 22(5): 459-462.
[3]	赵安玉琢, 石兴莲, 刘欢, 姜健红, 李哲臻, 刘梅. 人工智能在口腔癌早期诊断中的应用研究进展[J]. 中国口腔颌面外科杂志, 2024, 22(5): 493-498.
[4]	赵慧, 舒欣, 张帆, 任伟伟, 刘姣, 朱珠. 基于生物信息学和体外实验筛选头颈鳞癌生物标志物[J]. 中国口腔颌面外科杂志, 2024, 22(4): 329-338.
[5]	徐晨, 马丽娟, 石尧, 文玉珍, 宋永海, 车宗刚. 腮腺区炎性肌纤维母细胞瘤1例报告及文献复习[J]. 中国口腔颌面外科杂志, 2024, 22(4): 413-416.
[6]	王延安, 秦中平, 郑家伟, 李春洁, 刘少华, 杨耀武, 陈刚, 陈伟良, 刘学键, 杜仲, 张雷, 王业飞, 王德明, 苏立新, 谢峰, 董长宪, 郭磊, 李凯, 顾松, 何悦, 张志愿. 头颈部血管瘤及脉管畸形手术治疗专家共识[J]. 中国口腔颌面外科杂志, 2024, 22(2): 105-117.
[7]	曾慧, 江花香, 胡彦昌, 杨丰瑞, 王军. 基于生物信息学分析筛选舌鳞癌的关键基因[J]. 中国口腔颌面外科杂志, 2023, 21(5): 452-460.
[8]	高安天, 梁易, 林梓桐. 腮腺造影螺旋CT对腮腺疾病的诊断价值探讨[J]. 中国口腔颌面外科杂志, 2023, 21(2): 158-162.
[9]	柳江龙, 贾芳, 王晓荣, 热伊莱·阿不都克热木, 吾尔古丽·阿力甫, 买买提吐逊·吐尔地. 超声造影对口腔颌面部鳞癌颈部转移性淋巴结的诊断价值评价[J]. 中国口腔颌面外科杂志, 2023, 21(2): 168-174.
[10]	李雪儿, 王正业, 买买提吐逊·吐尔地. 基于影像组学鉴定头颈部鳞状细胞癌患者HPV状态：诊断性meta分析[J]. 中国口腔颌面外科杂志, 2023, 21(1): 69-74.
[11]	庞超远, 马东洋, 张文凯, 王兵武, 刘东. 54例学龄前儿童颌面部骨折临床分析[J]. 中国口腔颌面外科杂志, 2022, 20(6): 586-589.
[12]	杨慧丽, 王宇帆, 王锋, 沈月洪, 杨宏宇. NLRP1在头颈部鳞癌中的表达及预后意义[J]. 中国口腔颌面外科杂志, 2022, 20(5): 429-436.
[13]	刘冰, 何悦, 彭歆, 孙长伏, 韩正学, 吴煜农, 彭利伟, 赵熠, 陶谦, 韩新光, 李劲松, 苏彤, 李波, 张雷, 胡砚平, 陈传俊, 李一, 李铁军, 赵怡芳. 牙源性角化囊肿诊疗中国专家共识[J]. 中国口腔颌面外科杂志, 2022, 20(3): 209-218.
[14]	黄金云, 张心怡, 鞠侯雨, 冀洪海, 任国欣. 口腔微生物稳态与口腔鳞癌患者顺铂敏感性的相关性分析[J]. 中国口腔颌面外科杂志, 2021, 19(6): 500-505.
[15]	黄金云, 张心怡, 鞠侯雨, 冀洪海, 任国欣. 口腔微生物稳态与口腔鳞癌患者顺铂敏感性的相关性分析[J]. 中国口腔颌面外科杂志, 2021, 19(6): 506-510.